Publications & Posters

Title	Author	Reference	Sample Type	Patient Count	Primary Endpoint
	{{pub.author}}	{{pub.journal}},	{{sample}}	{{pub.patients}}	{{endpoint}}

Title	Author	Reference	Sample Type	Patient Count
	{{pub.author}}	{{pub.journal}},	{{sample}}	{{pub.patients}}

Title	Author	Reference	Sample Type
	{{pub.author}}	{{pub.journal}},	{{sample}}

Title	Author	Reference
	{{pub.author}}	{{pub.journal}},

2020
Conference: {{pub.conference}}
2019
Conference: {{pub.conference}}
2018
Conference: {{pub.conference}}
2017
Conference: {{pub.conference}}
2016
Conference: {{pub.conference}}
2015
Conference: {{pub.conference}}
2014
Conference: {{pub.conference}}
2013
Conference: {{pub.conference}}
2012
Conference: {{pub.conference}}
2011
Conference: {{pub.conference}}

Prolaris® Validated Weighted Algorithm - combines molecular and clinical features:

Hover Over Each Section to Learn More

CCR = 0.39 x CAPRA + 0.57 x CCP

Combined Clinical Risk Score

CCR is used to predict outcomes such as Disease Specific Mortality (DSM) and Metastasis (METs). Clinical decisions should be based on DSM and METs risk shown on the Prolaris results.

Weighted elements were validated in Cuzick et al. (2015)

- Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer. 2015;113(3):382-389. Doi: 10.1038/bjc.2015.

Cancer of the Prostate Risk Assessment Score

The score is calculated using points assigned to: age at diagnosis, PSA at diagnosis, Gleason score of the biopsy, clinical stage and percent of biopsy cores involved with cancer. The scale of this score is 0-10.

https://urology.ucsf.edu/research/cancer/prostate-cancer-risk-assessment-and-the-ucsf-capra-score

Cell Cycle Progression Score

CCP measures the activity of the cell cycle progression genes and is the molecular component of the Prolaris test. Do not use CCP alone for clinical decisions. The approximate scale of this score is about 1-11.

Prolaris® provides similar risks for different cohorts, demonstrating reproducibility

Compare risks curves using CCR for Cuzick et al 2012 and Cuzick et al 2015:

Red line based on Cuzick et al 2015 cohort; green line on Cuzick et al 2012 cohort. Ticks represent observed CCR scores.

- Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. British Journal of Cancer. 2012; 106(6):1095-1099. doi:10.1038/bjc.2012.39
- Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer. 2015;113(3):382-389. Doi: 10.1038/bjc.2015.223